久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Europe

UK approves Novavax's jab for novel coronavirus

By ANGUS McNEICE in London | China Daily Global | Updated: 2022-02-08 10:04
Share
Share - WeChat
A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020. [Photo/Agencies]

The United Kingdom drug regulator has approved a COVID-19 vaccine from United States pharmaceutical company Novavax, becoming the fifth jab to get the green light in the UK, and the first protein-based shot to enter the market.

The UK Medicines and Healthcare products Regulatory Agency, or MHRA, granted regulatory approval for use in adults aged 18 and above, after the jab, which is called Nuvaxovid, was deemed safe and conferred 89.7 percent protection against infection in a phase-3 trial of 15,000 participants in Britain.

That study, which was published in the New England Journal of Medicine, followed on from a separate late-stage trial of 30,000 participants in the US and Mexico, which achieved 90.4 percent efficacy overall.

The UK has already ordered 60 million doses of the vaccine, which is administered in a two-dose regimen, 21 days apart.

"It is great to see our world-renowned medicines regulator approve another COVID-19 vaccine," said UK Health Secretary Sajid Javid. "The next step will be for the independent Joint Committee on Vaccination and Immunisation to consider its use as part of the UK COVID-19 vaccination program."

Nuvaxovid has gained approval in several countries over the last few months including South Africa, India, South Korea and Australia, and Novavax has submitted the treatment for approval to US regulators.

The company is poised to emerge as one of the largest distributors of COVID-19 vaccines in 2022, with plans to manufacture 2.44 billion doses. This would place it in the top five manufacturers this year, along with Pfizer (4.1 billion), Sinovac (1.88 billion), Sinopharm (1.85 billion) and AstraZeneca (1.75 billion), according to projections provided to China Daily by science consultancy Airfinity.

Novavax was bookmarked last year as one of the most promising COVID-19 treatments, following encouraging results in early trials. The jab has a long shelf life of nine months, and does not require ultracold storage. This makes the treatment ideal for distribution in the developing world, and the COVAX vaccine equity project reserved 350 million shots in May 2021.

However, development of the jab has been significantly delayed. Novavax is a relatively small company, and a number of supply and manufacturing issues pushed distribution back to 2022.

The shot from Novavax is the first protein-based COVID-19 vaccine to gain approval in the UK, and experts say that having different varieties of jabs is key to maintaining robust protection in populations against the novel coronavirus. Already in use in treatments for other diseases including Hepatitis B, the technology involves injecting a protein into the body that encourages an immune response, rather than introducing genetic material, as is the case in mRNA vaccines, or using inactivated virus, as seen in several currently available COVID-19 jabs.

June Raine, MHRA chief executive, said the approval followed a "rigorous review of the safety, quality and effectiveness of this vaccine".

Novavax said that serious side effects to the vaccine were low in clinical trials, and the most commonly-reported reactions included headache, nausea or vomiting, muscle pain, joint stiffness, injection site tenderness and fatigue.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 亚洲一区二区三区在线播放 | 欧美精品网站 | 99久久精品一区二区三区 | 欧美一区精品二区三区 | 分享一个无毒不卡免费国产 | 中文字幕日韩三级 | 免费国产不卡午夜福在线观看 | 国产毛片久久精品 | 在线观看国内自拍 | 欧美国产在线视频 | 国产精品亚洲专一区二区三区 | 亚洲一区网站 | 91热视频在线观看 | 一级一级一片免费高清 | 日本b站一卡二卡乱码入口 日本s色大片在线观看 | 国产精品夜色视频一区二区 | 日韩免费一区二区三区 | 久久免费视频2 | 日本特爽特黄特刺激大片 | 精品国产一区二区三区不卡蜜臂 | 看真人视频a级毛片 | 亚洲免费不卡 | 国产成人精品视频免费大全 | 久久免费在线观看 | 亚洲国产系列久久精品99人人 | 日韩在线二区全免费 | 成人手机看片 | 国产午夜精品一区二区 | 亚洲第一影院 | 写真片福利视频在线播放 | 亚洲欧美日韩中文字幕在线一 | 久久两性 | 日本免费人做人一区在线观看 | 蜜桃欧美性大片 | 韩国美女爽快毛片免费 | 久久是精品 | 97se狠狠狠狠狠亚洲综合网 | 中日韩欧美一级毛片 | 国产成人精品男人的天堂网站 | 国产精品久久久久久影视 | 六月丁香婷婷天天在线 |